Literature DB >> 27981579

Pharmacogenetic Implementation Lessons From the "Real World".

D M Roden1.   

Abstract

The manuscript "Anticoagulation Endpoints With Clinical Implementation of Warfarin Pharmacogenetic Dosing in a Real- World Setting: A Proposal for a New Pharmacogenetic Dosing Approach" describes process outcomes in an institutional program to use pharmacogenetic testing to optimize warfarin dose in a cohort of 257 patients of diverse ancestries. The strengths and weaknesses of the approach and program are discussed, along with the current and potential future status of warfarin as a model for pharmacogenetic testing.
© 2016 ASCPT.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27981579      PMCID： PMC5474210          DOI： 10.1002/cpt.584

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  9 in total

1.  Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy.

Authors:  H Furuya; P Fernandez-Salguero; W Gregory; H Taber; A Steward; F J Gonzalez; J R Idle
Journal:  Pharmacogenetics       Date:  1995-12

2.  Genetic risk factors for major bleeding in patients treated with warfarin in a community setting.

Authors:  J A Roth; D Boudreau; M M Fujii; F M Farin; A E Rettie; K E Thummel; D L Veenstra
Journal:  Clin Pharmacol Ther       Date:  2014-02-06       Impact factor: 6.875

3.  Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.

Authors:  Mark J Rieder; Alexander P Reiner; Brian F Gage; Deborah A Nickerson; Charles S Eby; Howard L McLeod; David K Blough; Kenneth E Thummel; David L Veenstra; Allan E Rettie
Journal:  N Engl J Med       Date:  2005-06-02       Impact factor: 91.245

4.  A pharmacogenetic versus a clinical algorithm for warfarin dosing.

Authors:  Stephen E Kimmel; Benjamin French; Scott E Kasner; Julie A Johnson; Jeffrey L Anderson; Brian F Gage; Yves D Rosenberg; Charles S Eby; Rosemary A Madigan; Robert B McBane; Sherif Z Abdel-Rahman; Scott M Stevens; Steven Yale; Emile R Mohler; Margaret C Fang; Vinay Shah; Richard B Horenstein; Nita A Limdi; James A S Muldowney; Jaspal Gujral; Patrice Delafontaine; Robert J Desnick; Thomas L Ortel; Henny H Billett; Robert C Pendleton; Nancy L Geller; Jonathan L Halperin; Samuel Z Goldhaber; Michael D Caldwell; Robert M Califf; Jonas H Ellenberg
Journal:  N Engl J Med       Date:  2013-11-19       Impact factor: 91.245

5.  Genotype and risk of major bleeding during warfarin treatment.

Authors:  Vivian K Kawai; Andrew Cunningham; Susan I Vear; Sara L Van Driest; Abimbola Oginni; Hua Xu; Min Jiang; Chun Li; Joshua C Denny; Christian Shaffer; Erica Bowton; Brian F Gage; Wayne A Ray; Dan M Roden; C Michael Stein
Journal:  Pharmacogenomics       Date:  2014-12       Impact factor: 2.533

6.  Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting: A proposal for a new pharmacogenetic dosing approach.

Authors:  M J Arwood; J Deng; K Drozda; O Pugach; E A Nutescu; S Schmidt; J D Duarte; L H Cavallari
Journal:  Clin Pharmacol Ther       Date:  2016-12-29       Impact factor: 6.875

7.  Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2.

Authors:  Simone Rost; Andreas Fregin; Vytautas Ivaskevicius; Ernst Conzelmann; Konstanze Hörtnagel; Hans-Joachim Pelz; Knut Lappegard; Erhard Seifried; Inge Scharrer; Edward G D Tuddenham; Clemens R Müller; Tim M Strom; Johannes Oldenburg
Journal:  Nature       Date:  2004-02-05       Impact factor: 49.962

8.  A randomized trial of genotype-guided dosing of warfarin.

Authors:  Munir Pirmohamed; Girvan Burnside; Niclas Eriksson; Andrea L Jorgensen; Cheng Hock Toh; Toby Nicholson; Patrick Kesteven; Christina Christersson; Bengt Wahlström; Christina Stafberg; J Eunice Zhang; Julian B Leathart; Hugo Kohnke; Anke H Maitland-van der Zee; Paula R Williamson; Ann K Daly; Peter Avery; Farhad Kamali; Mia Wadelius
Journal:  N Engl J Med       Date:  2013-11-19       Impact factor: 91.245

9.  Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.

Authors:  Minoli A Perera; Larisa H Cavallari; Nita A Limdi; Eric R Gamazon; Anuar Konkashbaev; Roxana Daneshjou; Anna Pluzhnikov; Dana C Crawford; Jelai Wang; Nianjun Liu; Nicholas Tatonetti; Stephane Bourgeois; Harumi Takahashi; Yukiko Bradford; Benjamin M Burkley; Robert J Desnick; Jonathan L Halperin; Sherief I Khalifa; Taimour Y Langaee; Steven A Lubitz; Edith A Nutescu; Matthew Oetjens; Mohamed H Shahin; Shitalben R Patel; Hersh Sagreiya; Matthew Tector; Karen E Weck; Mark J Rieder; Stuart A Scott; Alan H B Wu; James K Burmester; Mia Wadelius; Panos Deloukas; Michael J Wagner; Taisei Mushiroda; Michiaki Kubo; Dan M Roden; Nancy J Cox; Russ B Altman; Teri E Klein; Yusuke Nakamura; Julie A Johnson
Journal:  Lancet       Date:  2013-06-05       Impact factor: 79.321
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.